182 related articles for article (PubMed ID: 9151941)
1. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
Albert DH; Magoc TJ; Tapang P; Luo G; Morgan DW; Curtin M; Sheppard GS; Xu L; Heyman HR; Davidsen SK; Summers JB; Carter GW
Eur J Pharmacol; 1997 Apr; 325(1):69-80. PubMed ID: 9151941
[TBL] [Abstract][Full Text] [Related]
2. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
Albert DH; Conway RG; Magoc TJ; Tapang P; Rhein DA; Luo G; Holms JH; Davidsen SK; Summers JB; Carter GW
J Pharmacol Exp Ther; 1996 Jun; 277(3):1595-606. PubMed ID: 8667228
[TBL] [Abstract][Full Text] [Related]
3. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
Albert DH; Malo PE; Tapang P; Shaughnessy TK; Morgan DW; Wegner CD; Curtin ML; Sheppard GS; Xu L; Davidsen SK; Summers JB; Carter GW
J Pharmacol Exp Ther; 1998 Jan; 284(1):83-8. PubMed ID: 9435164
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
6. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
9. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist.
Kruse-Elliott KT; Albert DH; Summers JB; Carter GW; Zimmerman JJ; Grossman JE
Shock; 1996 Apr; 5(4):265-73. PubMed ID: 8721386
[TBL] [Abstract][Full Text] [Related]
12. (+/-)-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist.
Ponpipom MM; Hwang SB; Doebber TW; Acton JJ; Alberts AW; Biftu T; Brooker DR; Bugianesi RL; Chabala JC; Gamble NL
Biochem Biophys Res Commun; 1988 Feb; 150(3):1213-20. PubMed ID: 2829894
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin.
Sanz MJ; Weg VB; Walsh DT; Williams TJ; Nourshargh S
Br J Pharmacol; 1994 Oct; 113(2):513-21. PubMed ID: 7834203
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Curtin ML; Davidsen SK; Heyman HR; Garland RB; Sheppard GS; Florjancic AS; Xu L; Carrera GM; Steinman DH; Trautmann JA; Albert DH; Magoc TJ; Tapang P; Rhein DA; Conway RG; Luo G; Denissen JF; Marsh KC; Morgan DW; Summers JB
J Med Chem; 1998 Jan; 41(1):74-95. PubMed ID: 9438024
[TBL] [Abstract][Full Text] [Related]
16. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
17. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Albert DH; Luo G; Magoc TJ; Tapang P; Holms JH; Davidsen SK; Summers JB; Carter GW
Shock; 1996 Aug; 6(2):112-7. PubMed ID: 8856845
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.
Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X; Han GQ; Li RZ
Proc Natl Acad Sci U S A; 1985 Feb; 82(3):672-6. PubMed ID: 2983307
[TBL] [Abstract][Full Text] [Related]
19. ABT-299, a potent antagonist of platelet activating factor.
Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
[No Abstract] [Full Text] [Related]
20. Treatment with a platelet-activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock.
Tacquard C; Oulehri W; Collange O; Garvey LH; Nicoll S; Tuzin N; Geny B; Mertes PM
Clin Exp Allergy; 2020 Mar; 50(3):383-390. PubMed ID: 31755606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
